LIGA 20

a semisynthetic GM1 ganglioside with N-dichloroacetylsphingosine; about ten times more potent than the natural GM2 in protecting neurons in culture against glutamate toxicity

Also Known As:

II3Neu5-AcGgOse4-2-d-erythro-1,3-dihydroxy-2-dichloroacetamide-4-trans-octadacene; LIGA-20; LIGA20; Acetamide, N-(1-(((O-(N-acetyl-alpha-neuraminosyl)-(2-3)-O-(O-beta-D-galactopyranosyl-(1-3)-2-(acetylamino)-2-deoxy-beta-D-galactopyranosyl-(1-4))-O-beta-D-galactopyranosyl-(1-4)-beta-D-glucopyranosyl)oxy)methyl)-2-hydroxy-3-heptadecenyl)-2,2-dichloro-, (R-(R*,S*-(E)))-

Networked: 7 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Wu, Gusheng: 5 articles (09/2011 - 11/2005)
2.	Ledeen, Robert W: 4 articles (09/2011 - 11/2005)
3.	Lu, Zi-Hua: 2 articles (09/2011 - 11/2005)
4.	Amin, Ruchi: 1 article (09/2011)
5.	Kulkarni, Neil: 1 article (09/2011)
6.	Ledeen, Robert: 1 article (11/2007)
7.	Meyenhofer, Markus F: 1 article (11/2005)
8.	Wang, Jianfeng: 1 article (11/2005)
9.	Wang, Yvette: 1 article (11/2005)
10.	Xie, Xin: 1 article (11/2005)

Related Diseases

1.	Seizures (Absence Seizure) 04/01/2006 - "As further indication of Ca2+ dysregulation, the mutant mice were highly susceptible to kainite-induced seizures which were attenuated by LIGA-20. " 03/01/2006 - "The seizures were effectively attenuated by LIGA20 in parallel with the ability of this agent to enter brain cells, insert into the NE, and potentiate Na(+)/Ca(2+) exchange activity in the nucleus. " 11/01/2007 - "Further indication came from a study of the mutant mice, which were highly susceptible to kainate-induced seizures and could be rescued by LIGA-20. " 11/23/2005 - "Enhanced susceptibility to kainate-induced seizures, neuronal apoptosis, and death in mice lacking gangliotetraose gangliosides: protection with LIGA 20, a membrane-permeant analog of GM1."
2.	Infarction (Infarctions) 07/05/1994 - "The N-dichloroacetylsphingosine derivative of lysoGM1 (LIGA20) administered after the lesion either i.v. or per or reduces the infarct size by 30-40% and attenuates the associated cognition deficits, presumably by limiting the extent of damage of neurons at risk located in the surroundings of the infarcted core (i.e., area penumbra). " 01/01/1994 - "Oral treatment with 100 mg/kg of LIGA20 reduced the infarct size in the cortex but not in the ischemic core (the striatum). " 07/05/1994 - "LIGA20, a lyso derivative of ganglioside GM1, given orally after cortical thrombosis reduces infarct size and associated cognition deficit." 01/01/1994 - "Orally administered glycolipid derivative LIGA20 reduces infarct volume and behavioral impairment after focal cerebral ischemia."
3.	Cognitive Dysfunction 01/01/1994 - "Oral administration of 50 to 200 mg/kg of LIGA20, initiated 24 hr before middle cerebral artery occlusion and continued for 7 days, reduced the motor and cognitive impairment after the stroke, measured by the rotarod and the passive avoidance test, respectively. "
4.	Parkinsonian Disorders (Parkinsonism) 09/01/2011 - "These manifestations of parkinsonism were largely attenuated by administration of LIGA-20, a membrane permeable analog of GM1 that penetrates the blood brain barrier and enters living neurons. "
5.	Stroke (Strokes) 01/01/1994 - "semisynthetic glycolipid LIGA20 (II3Neu5-AcGgOse4-2-d-erythro-1,3-dihydroxy-2-dichloro-aceta mide-4-trans- octadecene) treatment in stroke was studied in a permanent left middle cerebral artery occlusion model in the rat. " 01/01/1994 - "Oral administration of 50 to 200 mg/kg of LIGA20, initiated 24 hr before middle cerebral artery occlusion and continued for 7 days, reduced the motor and cognitive impairment after the stroke, measured by the rotarod and the passive avoidance test, respectively. "

Related Drugs and Biologics

1.	Kainic Acid (Kainate)
2.	Glycolipids
3.	Gangliosides
4.	G(M1) Ganglioside
5.	gangliotetraose

Related Therapies and Procedures

1.	Oral Administration

HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Application Error

An application error has occurred and our support engineers have been notified.

Please use the browser "Back" button and try your operation again.

OR if the error persists and you require an email response
please contact us at "cs at curehunter.com":

Your request
The circumstances of the error
Your login id/nickname or email

Return to Top Page